Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes
Jerry Usary1, David Brian Darr1, Adam D Pfefferle1
1Deptartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
Abstract:
Advances in the screening of new therapeutic options have significantly reduced the breast cancer death rate over the last decade. Despite these advances, breast cancer remains the second leading cause of cancer death among women. This is due in part to the complexity of the disease, which is characterized by multiple subtypes that are driven by different genetic mechanisms and that likely arise from different cell types of origin. Because these differences often drive treatment options and outcomes, it is important to select relevant preclinical model systems to study new therapeutic interventions and tumor biology. Described in this unit are the characteristics and applications of validated genetically engineered mouse models (GEMMs) of basal-like, luminal, and claudin-low human subtypes of breast cancer. These different subtypes have different clinical outcomes and require different treatment strategies. These GEMMs can be considered faithful surrogates of their human disease counterparts. They represent alternative preclinical tumor models to cell line and patient-derived xenografts for preclinical drug discovery and tumor biology studies.
Insights
Genetically engineered mouse models (GEMMs) accurately mimic human breast cancer subtypes, aiding in the development of targeted therapies. These models offer a valuable preclinical tool for advancing breast cancer research and drug discovery.
Area of Science:
- Oncology
- Translational Medicine
- Genetics
Background:
- Breast cancer remains a leading cause of cancer death in women despite therapeutic advances.
- The disease's complexity, with diverse subtypes driven by distinct genetic mechanisms, necessitates tailored treatment strategies.
- Selecting appropriate preclinical models is crucial for studying tumor biology and evaluating new therapeutic interventions.
Purpose of the Study:
- To describe the characteristics and applications of validated genetically engineered mouse models (GEMMs) for studying human breast cancer subtypes.
- To highlight the utility of GEMMs as preclinical models for drug discovery and tumor biology research.
Main Methods:
- Utilized genetically engineered mouse models (GEMMs) that recapitulate key features of human breast cancer subtypes.
- Validated GEMMs representing basal-like, luminal, and claudin-low breast cancer subtypes.
- Assessed GEMMs as surrogates for human disease in preclinical studies.
Main Results:
- GEMMs accurately reflect the distinct genetic drivers and characteristics of human breast cancer subtypes.
- These models demonstrate differential clinical outcomes and therapeutic responses consistent with human subtypes.
- GEMMs serve as faithful preclinical surrogates for their human counterparts.
Conclusions:
- Validated GEMMs provide a powerful tool for advancing breast cancer research and preclinical drug discovery.
- These models are essential for understanding subtype-specific tumor biology and developing targeted therapies.
- GEMMs represent a valuable alternative to cell lines and patient-derived xenografts for breast cancer research.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study